Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix

J. B. Vermorken, C. Mangioni, S. Pecorelli, M. E L Van Der Burg, A. T. Van Oosterom, W. W. Ten Bokkel Huinink, N. Rotmensz, O. Dalesio

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The objective of this study was to study the antitumor activity of the vincristine, bleomycin, mitomycin C and cisplatin (VBMP) scheme in patients with disseminated squamous cell carcinoma of the uterine cervix and to document its toxicity. VBMP consisted of vincristine 1.4 mg/m2 (max. 2 mg) i.v. day 1, bleomycin 15 mg/day by continuous i.v. infusion on day 1 + 2, mitomycin C 6 mg/m2 i.v. day 3 and cisplatin 50 mg/m2 i.v. day 4, and was given every 4 weeks. Bleomycin was withdrawn from the schedule after a cumulative dose of 300 mg (210 mg in patients over 60). Thereafter VMP continued (V + M day 1, P day 2) with the same interval. A median number of 4.5 (range 2-13) treatment cycles was given to 50 fully evaluable patients, 26 with only distant metastases (group A) and 24 with pelvic disease also (23 previously irradiated) (group B). All patients were <70 years old, had a Karnofsky index ≥60, and measurable metastatic lesions outside previously irradiated areas. They all had normal organ functions and gave informed consent. Response in group A was 54% (31% complete), in group B 25% (all partial), 40% in all. Median time to progression in group A was 20 weeks and in group B 15 weeks; median survival was 42 weeks in group A, 32 weeks in group B, 37 weeks for all patients. Hematologic toxicity was cumulative and the majority of patients needed blood transfusions. Nonhematologic toxicity was acceptable, but in one patient pulmonary toxicity might have contributed to death. Although it is active, it is unclear whether this regimen is superior to cisplatin alone.

Original languageEnglish
Pages (from-to)358-365
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume10
Issue number5
DOIs
Publication statusPublished - 2000

Fingerprint

Bleomycin
Mitomycin
Vincristine
Cervix Uteri
Cisplatin
Squamous Cell Carcinoma
Karnofsky Performance Status
Informed Consent
Blood Transfusion
Appointments and Schedules
Neoplasm Metastasis
Lung
Survival

Keywords

  • Cervical cancer
  • Chemotherapy
  • Metastatic disease

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Vermorken, J. B., Mangioni, C., Pecorelli, S., Van Der Burg, M. E. L., Van Oosterom, A. T., Ten Bokkel Huinink, W. W., ... Dalesio, O. (2000). Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. International Journal of Gynecological Cancer, 10(5), 358-365. https://doi.org/10.1046/j.1525-1438.2000.010005358.x

Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. / Vermorken, J. B.; Mangioni, C.; Pecorelli, S.; Van Der Burg, M. E L; Van Oosterom, A. T.; Ten Bokkel Huinink, W. W.; Rotmensz, N.; Dalesio, O.

In: International Journal of Gynecological Cancer, Vol. 10, No. 5, 2000, p. 358-365.

Research output: Contribution to journalArticle

Vermorken, J. B. ; Mangioni, C. ; Pecorelli, S. ; Van Der Burg, M. E L ; Van Oosterom, A. T. ; Ten Bokkel Huinink, W. W. ; Rotmensz, N. ; Dalesio, O. / Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. In: International Journal of Gynecological Cancer. 2000 ; Vol. 10, No. 5. pp. 358-365.
@article{8f8f0fb4453e45b7afc2eaa5d8b1c171,
title = "Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix",
abstract = "The objective of this study was to study the antitumor activity of the vincristine, bleomycin, mitomycin C and cisplatin (VBMP) scheme in patients with disseminated squamous cell carcinoma of the uterine cervix and to document its toxicity. VBMP consisted of vincristine 1.4 mg/m2 (max. 2 mg) i.v. day 1, bleomycin 15 mg/day by continuous i.v. infusion on day 1 + 2, mitomycin C 6 mg/m2 i.v. day 3 and cisplatin 50 mg/m2 i.v. day 4, and was given every 4 weeks. Bleomycin was withdrawn from the schedule after a cumulative dose of 300 mg (210 mg in patients over 60). Thereafter VMP continued (V + M day 1, P day 2) with the same interval. A median number of 4.5 (range 2-13) treatment cycles was given to 50 fully evaluable patients, 26 with only distant metastases (group A) and 24 with pelvic disease also (23 previously irradiated) (group B). All patients were <70 years old, had a Karnofsky index ≥60, and measurable metastatic lesions outside previously irradiated areas. They all had normal organ functions and gave informed consent. Response in group A was 54{\%} (31{\%} complete), in group B 25{\%} (all partial), 40{\%} in all. Median time to progression in group A was 20 weeks and in group B 15 weeks; median survival was 42 weeks in group A, 32 weeks in group B, 37 weeks for all patients. Hematologic toxicity was cumulative and the majority of patients needed blood transfusions. Nonhematologic toxicity was acceptable, but in one patient pulmonary toxicity might have contributed to death. Although it is active, it is unclear whether this regimen is superior to cisplatin alone.",
keywords = "Cervical cancer, Chemotherapy, Metastatic disease",
author = "Vermorken, {J. B.} and C. Mangioni and S. Pecorelli and {Van Der Burg}, {M. E L} and {Van Oosterom}, {A. T.} and {Ten Bokkel Huinink}, {W. W.} and N. Rotmensz and O. Dalesio",
year = "2000",
doi = "10.1046/j.1525-1438.2000.010005358.x",
language = "English",
volume = "10",
pages = "358--365",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix

AU - Vermorken, J. B.

AU - Mangioni, C.

AU - Pecorelli, S.

AU - Van Der Burg, M. E L

AU - Van Oosterom, A. T.

AU - Ten Bokkel Huinink, W. W.

AU - Rotmensz, N.

AU - Dalesio, O.

PY - 2000

Y1 - 2000

N2 - The objective of this study was to study the antitumor activity of the vincristine, bleomycin, mitomycin C and cisplatin (VBMP) scheme in patients with disseminated squamous cell carcinoma of the uterine cervix and to document its toxicity. VBMP consisted of vincristine 1.4 mg/m2 (max. 2 mg) i.v. day 1, bleomycin 15 mg/day by continuous i.v. infusion on day 1 + 2, mitomycin C 6 mg/m2 i.v. day 3 and cisplatin 50 mg/m2 i.v. day 4, and was given every 4 weeks. Bleomycin was withdrawn from the schedule after a cumulative dose of 300 mg (210 mg in patients over 60). Thereafter VMP continued (V + M day 1, P day 2) with the same interval. A median number of 4.5 (range 2-13) treatment cycles was given to 50 fully evaluable patients, 26 with only distant metastases (group A) and 24 with pelvic disease also (23 previously irradiated) (group B). All patients were <70 years old, had a Karnofsky index ≥60, and measurable metastatic lesions outside previously irradiated areas. They all had normal organ functions and gave informed consent. Response in group A was 54% (31% complete), in group B 25% (all partial), 40% in all. Median time to progression in group A was 20 weeks and in group B 15 weeks; median survival was 42 weeks in group A, 32 weeks in group B, 37 weeks for all patients. Hematologic toxicity was cumulative and the majority of patients needed blood transfusions. Nonhematologic toxicity was acceptable, but in one patient pulmonary toxicity might have contributed to death. Although it is active, it is unclear whether this regimen is superior to cisplatin alone.

AB - The objective of this study was to study the antitumor activity of the vincristine, bleomycin, mitomycin C and cisplatin (VBMP) scheme in patients with disseminated squamous cell carcinoma of the uterine cervix and to document its toxicity. VBMP consisted of vincristine 1.4 mg/m2 (max. 2 mg) i.v. day 1, bleomycin 15 mg/day by continuous i.v. infusion on day 1 + 2, mitomycin C 6 mg/m2 i.v. day 3 and cisplatin 50 mg/m2 i.v. day 4, and was given every 4 weeks. Bleomycin was withdrawn from the schedule after a cumulative dose of 300 mg (210 mg in patients over 60). Thereafter VMP continued (V + M day 1, P day 2) with the same interval. A median number of 4.5 (range 2-13) treatment cycles was given to 50 fully evaluable patients, 26 with only distant metastases (group A) and 24 with pelvic disease also (23 previously irradiated) (group B). All patients were <70 years old, had a Karnofsky index ≥60, and measurable metastatic lesions outside previously irradiated areas. They all had normal organ functions and gave informed consent. Response in group A was 54% (31% complete), in group B 25% (all partial), 40% in all. Median time to progression in group A was 20 weeks and in group B 15 weeks; median survival was 42 weeks in group A, 32 weeks in group B, 37 weeks for all patients. Hematologic toxicity was cumulative and the majority of patients needed blood transfusions. Nonhematologic toxicity was acceptable, but in one patient pulmonary toxicity might have contributed to death. Although it is active, it is unclear whether this regimen is superior to cisplatin alone.

KW - Cervical cancer

KW - Chemotherapy

KW - Metastatic disease

UR - http://www.scopus.com/inward/record.url?scp=0033710830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033710830&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.2000.010005358.x

DO - 10.1046/j.1525-1438.2000.010005358.x

M3 - Article

AN - SCOPUS:0033710830

VL - 10

SP - 358

EP - 365

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -